ALK and non-small cell lung carcinoma: Based on the ORRs of 50% and 61% and the PFS of 41.9 and 48.1 weeks in two single‐arm phase I and II clinical trials (expansion cohort of PROFILE 1001 and PROFILE 1005), crizotinib has been approved by the U.S. FDA in 2011 for advanced NSCLC patients with ALK rearrangements.155